156 related articles for article (PubMed ID: 16687477)
1. Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake.
Rau KS; Birdsall E; Volz TJ; Riordan JA; Baucum AJ; Adair BP; Bitter R; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2006 Aug; 318(2):676-82. PubMed ID: 16687477
[TBL] [Abstract][Full Text] [Related]
2. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
3. Methamphetamine rapidly decreases vesicular dopamine uptake.
Brown JM; Hanson GR; Fleckenstein AE
J Neurochem; 2000 May; 74(5):2221-3. PubMed ID: 10800970
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Yasumoto S; Tamura K; Karasawa J; Hasegawa R; Ikeda K; Yamamoto T; Yamamoto H
Neurosci Lett; 2009 May; 454(3):229-32. PubMed ID: 19429089
[TBL] [Abstract][Full Text] [Related]
5. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
[TBL] [Abstract][Full Text] [Related]
6. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
[TBL] [Abstract][Full Text] [Related]
7. Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.
McFadden LM; Hunt MM; Vieira-Brock PL; Muehle J; Nielsen SM; Allen SC; Hanson GR; Fleckenstein AE
Drug Alcohol Depend; 2012 Nov; 126(1-2):87-94. PubMed ID: 22647900
[TBL] [Abstract][Full Text] [Related]
8. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.
Hadlock GC; Chu PW; Walters ET; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2010 Oct; 335(1):207-12. PubMed ID: 20622144
[TBL] [Abstract][Full Text] [Related]
9. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.
Chu PW; Hadlock GC; Vieira-Brock P; Stout K; Hanson GR; Fleckenstein AE
J Neurochem; 2010 Oct; 115(2):325-32. PubMed ID: 20649837
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
[TBL] [Abstract][Full Text] [Related]
12. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Horton DB; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Oct; 339(1):286-97. PubMed ID: 21778282
[TBL] [Abstract][Full Text] [Related]
13. Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.
Hanson JE; Birdsall E; Seferian KS; Crosby MA; Keefe KA; Gibb JW; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2009 Apr; 607(1-3):68-73. PubMed ID: 19326567
[TBL] [Abstract][Full Text] [Related]
14. Age-dependent effects of methamphetamine on VMAT-2.
Rau KS; Truong JG; Wilkins DG; Fleckenstein AE; Hanson GR
Ann N Y Acad Sci; 2006 Aug; 1074():154-9. PubMed ID: 17105913
[TBL] [Abstract][Full Text] [Related]
15. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
Eyerman DJ; Yamamoto BK
J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
McFadden LM; Hadlock GC; Allen SC; Vieira-Brock PL; Stout KA; Ellis JD; Hoonakker AJ; Andrenyak DM; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2012 Feb; 340(2):295-303. PubMed ID: 22034657
[TBL] [Abstract][Full Text] [Related]
17. Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo.
Meyer AC; Neugebauer NM; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
J Neurochem; 2013 Oct; 127(2):187-98. PubMed ID: 23875705
[TBL] [Abstract][Full Text] [Related]
18. Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity.
Guilarte TR; Nihei MK; McGlothan JL; Howard AS
Neuroscience; 2003; 122(2):499-513. PubMed ID: 14614914
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.
Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
Synapse; 2009 Feb; 63(2):147-51. PubMed ID: 19021208
[TBL] [Abstract][Full Text] [Related]
20. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.
Guillot TS; Shepherd KR; Richardson JR; Wang MZ; Li Y; Emson PC; Miller GW
J Neurochem; 2008 Sep; 106(5):2205-17. PubMed ID: 18643795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
